Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose ICE with Amifostine
NCT00003657Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 1998
- Primary completion
- Nov 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amifostine in bladder cancer, central nervous system tumor, carcinoma of unknown primary (CUP) and 8 more, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Percentage of Participants with Grade 2 or higher renal toxicities at 2 months. Started Jul 1998; status: completed.
02
Drugs
amifostine
03
Conditions
bladder cancercentral nervous system tumorcarcinoma of unknown primary (CUP)germ cell tumor (GCT)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00003657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003657.